2. Academic Validation
  3. A Focused Screen Identifies Antifolates with Activity on Mycobacterium tuberculosis

A Focused Screen Identifies Antifolates with Activity on Mycobacterium tuberculosis

  • ACS Infect Dis. 2015 Dec 11;1(12):604-14. doi: 10.1021/acsinfecdis.5b00063.
Anuradha Kumar 1,  Ana Guardia 2,  Gonzalo Colmenarejo 3,  Esther Pérez 2,  Ruben R Gonzalez 2,  Pedro Torres 2,  David Calvo 2,  Ruben M Gómez 2,  Fátima Ortega 2,  Elena Jiménez 2,  Raquel C Gabarro 2,  Joaquín Rullás 2,  Lluis Ballell 2,  David R Sherman 1 4
Affiliations

Affiliations

  • 1 Center for Infectious Disease Research (Formerly Seattle Biomedical Research Institute) , Suite 500, Westlake Avenue North, Seattle, Washington 98109, United States.
  • 2 Diseases of the Developing World, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain.
  • 3 Centro de Investigación Básica, CSci Computational Chemistry, Platform Technologies and Science, Parque Tecnológico de Madrid , 28760 Tres Cantos, Madrid, Spain.
  • 4 Interdisciplinary Program of Pathobiology, Department of Global Health, University of Washington , Seattle, Washington 98195, United States.
PMID: 26771003 DOI: 10.1021/acsinfecdis.5b00063
Abstract

Antifolates are widely used to treat several diseases but are not currently used in the first-line treatment of tuberculosis, despite evidence that some of these molecules can target Mycobacterium tuberculosis (Mtb) bacilli in vitro. To identify new Antifolate candidates for animal-model efficacy studies of tuberculosis, we paired knowledge and tools developed in academia with the infrastructure and chemistry resources of a large pharmaceutical company. Together we curated a focused library of 2508 potential antifolates, which were then tested for activity against live Mtb. We identified 210 primary hits, confirmed the on-target activity of potent compounds, and now report the identification and characterization of 5 hit compounds, representative of 5 different chemical scaffolds. These antifolates have potent activity against Mtb and represent good starting points for improvement that could lead to in vivo efficacy studies.

Keywords

antifolate; dihydrofolate reductase; trimetrexate; tuberculosis.

Figures
Products